Company intelligence / Profile preview

Neuraptive Therapeutics, Inc.

Wayne, Pennsylvania, United Statesneuraptive.com ↗

Ownership: Private
Employees: ~8
Development stage: Phase 2

Overview

NTX-001 has received FDA Breakthrough Therapy Designation following promising results from the Phase 2 NEUROFUSE study. The company is preparing to launch a Phase 3 pivotal program in early 2025. Full results from the Phase 2 study, including 48 weeks of data, are expected to be available soon.

Therapeutic areas: Neurology
Modalities: Fusion system for nerve repairdrug delivery devicemicrosurgical instruments
Industry: Biotech

Drug pipeline

2 assets

NTX-001

1 more asset in the full pipeline.

Request access →

Partnerships

University of Texas at Austin

Beyond the preview

Go deeper on Neuraptive Therapeutics, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neuraptive Therapeutics, Inc..

Explore the full profile